ImmunoGen Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ImmunoGen wird ein Gewinn- und Umsatzwachstum von 54.6% bzw. 48.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 53.7% pro Jahr wachsen soll.

Wichtige Informationen

54.6%

Wachstumsrate der Gewinne

53.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	35.4%
Wachstumsrate der Einnahmen	48.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

XTRA:IMU - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2024	256	-160	-173	-145	7
12/31/2023	126	-261	-234	-211	10
12/31/2022	85	-242	-302	-230	10
9/30/2022	96	-201	-217	-215	N/A
6/30/2022	89	-161	-187	-186	N/A
3/31/2022	92	-129	-167	-166	N/A
12/31/2021	70	-139	-171	-169	N/A
9/30/2021	128	-71	-116	-115	N/A
6/30/2021	137	-56	-112	-111	N/A
3/31/2021	135	-49	-97	-95	N/A
12/31/2020	132	-44	-80	-79	N/A
9/30/2020	91	-71	-121	-120	N/A
6/30/2020	86	-70	-125	-124	N/A
3/31/2020	87	-89	-128	-127	N/A
12/31/2019	82	-104	-91	-88	N/A
9/30/2019	51	-151	-101	-97	N/A
6/30/2019	48	-176	-107	-102	N/A
3/31/2019	42	-174	-113	-106	N/A
12/31/2018	53	-169	-172	-166	N/A
9/30/2018	79	-140	-159	-155	N/A
6/30/2018	77	-150	-71	-69	N/A
3/31/2018	107	-117	-11	-9	N/A
12/31/2017	115	-96	7	8	N/A
9/30/2017	90	-117	0	1	N/A
6/30/2017	89	-105	-95	-93	N/A
3/31/2017	57	-142	-153	-150	N/A
12/31/2016	49	-157	-149	-143	N/A
9/30/2016	53	-156	-149	-141	N/A
6/30/2016	60	-145	N/A	-124	N/A
3/31/2016	65	-129	N/A	-120	N/A
12/31/2015	57	-119	N/A	-86	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IMU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IMU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IMU wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IMUDie Einnahmen des Unternehmens (48.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.3% pro Jahr).

Hohe Wachstumseinnahmen: IMUDie Einnahmen des Unternehmens (48.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IMU in 3 Jahren voraussichtlich hoch sein wird

ImmunoGen Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

No longer forecast to breakeven

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

ImmunoGen, Inc. Announces Mature Data from Forward II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020)

ImmunoGen, Inc. Provides Revenue Guidance for the Year of 2021

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

Executive Officer has left the company

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

New 90-day high: €6.39

ImmunoGen, Inc. Enters into Collaboration and Option Agreement with Subsidiary of Jazz Pharmaceuticals plc

New 90-day high: €5.29

ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

Third quarter 2020 earnings released: US$0.13 loss per share

Revenue beats expectations

New 90-day high: €4.98

ImmunoGen, Inc. Announces Executive Changes, Effective on January 1, 2021

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Announces Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

New 90-day high: €4.63

ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

New 90-day low - €2.99

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken